Kate Haviland - 17 Jul 2025 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: BPMC
Reported as of: 17 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jul 2025, 19:47:19 UTC
Prior SEC filing: 30 Jun 2025
Next SEC filing: 29 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Melissa Masse, Attorney-in-Fact

Key filing fact

Kate Haviland filed Form 4 for Blueprint Medicines Corp (BPMC) on 21 Jul 2025.

Key facts

This page summarizes Kate Haviland's Form 4 filing for Blueprint Medicines Corp (BPMC).
13 reported transactions and 10 derivative rows are listed below.
Accepted by SEC: 21 Jul 2025, 19:47.

Change

Previous filing in this sequence was filed on 30 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001663022 Primary reporting owner

Haviland Kate

Relationship: Chief Executive Officer, Director
Address: C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE
Signature: /s/ Melissa Masse, Attorney-in-Fact
Signature date: 21 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BPMC transaction

Common Stock

Award

Transaction value
Shares: +129,210
Change %: +78%
Price
Shares after: 295,139
Date: 17 Jul 2025
Ownership: Direct
Footnotes: F1, F2, F3

BPMC transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -224,410
Change %: -76%
Price
Shares after: 70,729
Date: 17 Jul 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

BPMC transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -70,729
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Footnotes: F1, F2, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -2
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2
Exercise price: $16.28
Footnotes: F1, F2, F6

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -591
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 591
Exercise price: $36.05
Footnotes: F1, F2, F6

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -39,000
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 39,000
Exercise price: $81.44
Footnotes: F1, F2, F6

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -32,500
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,500
Exercise price: $86.60
Footnotes: F1, F2, F6

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -28,500
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,500
Exercise price: $54.13
Footnotes: F1, F2, F6

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -26,125
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,125
Exercise price: $100.13
Footnotes: F1, F2, F6

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -80,000
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $61.31
Footnotes: F1, F2, F6

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -80,000
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $43.15
Footnotes: F1, F2, F6

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -80,000
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $95.12
Footnotes: F1, F2, F6

BPMC transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -70,400
Change %: -100%
Price
Shares after: 0
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,400
Exercise price: $96.57
Footnotes: F1, F2, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Kate Haviland is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

Footnote F2

Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

Footnote F3

Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

Footnote F4

Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

Footnote F5

Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

Footnote F6

Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.